AI Tool Decodes Brain Cancer's Genome During Surgery

Scientists have designed an AI tool that can rapidly decode a brain tumor's DNA to determine its molecular identity during surgery - critical information that under the current approach can take a few days and up to a few weeks.

Knowing a tumor's molecular type enables neurosurgeons to make decisions such as how much brain tissue to remove and whether to place tumor-killing drugs directly into the brain - while the patient is still on the operating table.

A report on the work, led by Harvard Medical School researchers, is published July 7 in the journal Med.

Accurate molecular diagnosis - which details DNA alterations in a cell - during surgery can help a neurosurgeon decide how much brain tissue to remove. Removing too much when the tumor is less aggressive can affect a patient's neurologic and cognitive function. Likewise, removing too little when the tumor is highly aggressive may leave behind malignant tissue that can grow and spread quickly.

"Right now, even state-of-the-art clinical practice cannot profile tumors molecularly during surgery. Our tool overcomes this challenge by extracting thus-far untapped biomedical signals from frozen pathology slides," said study senior author Kun-Hsing Yu, assistant professor of biomedical informatics in the Blavatnik Institute at HMS.

Knowing a tumor's molecular identity during surgery is also valuable because certain tumors benefit from on-the-spot treatment with drug-coated wafers placed directly into the brain at the time of the operation, Yu said.

"The ability to determine intraoperative molecular diagnosis in real time, during surgery, can propel the development of real-time precision oncology," Yu added.

The standard intraoperative diagnostic approach used now involves taking brain tissue, freezing it, and examining it under a microscope. A major drawback is that freezing the tissue tends to alter the appearance of cells under a microscope and can interfere with the accuracy of clinical evaluation. Furthermore, the human eye, even when using potent microscopes, cannot reliably detect subtle genomic variations on a slide.

The new AI approach overcomes these challenges.

The tool, called CHARM (Cryosection Histopathology Assessment and Review Machine), is freely available to other researchers. It still has to be clinically validated through testing in real-world settings and cleared by the FDA before deployment in hospitals, the research team said.

Cracking cancer's molecular code

Recent advances in genomics have allowed pathologists to differentiate the molecular signatures - and the behaviors that such signatures portend - across various types of brain cancer as well as within specific types of brain cancer. For example, glioma - the most aggressive brain tumor and the most common form of brain cancer - has three main subvariants that carry different molecular markers and have different propensities for growth and spread.

The new tool's ability to expedite molecular diagnosis could be particularly valuable in areas with limited access to technology to perform rapid cancer genetic sequencing.

Beyond the decisions made during surgery, knowledge of a tumor’s molecular type provides clues about its aggressiveness, behavior, and likely response to various treatments. Such knowledge can inform post-operative decisions.

Furthermore, the new tool enables during-surgery diagnoses aligned with the World Health Organization’s recently updated classification system for diagnosing and grading the severity of gliomas, which calls for such diagnoses to be made based on a tumor's genomic profile.

Training CHARM

CHARM was developed using 2,334 brain tumor samples from 1,524 people with glioma from three different patient populations. When tested on a never-before-seen set of brain samples, the tool distinguished tumors with specific molecular mutations at 93 percent accuracy and successfully classified three major types of gliomas with distinct molecular features that carry different prognoses and respond differently to treatments.

Going a step further, the tool successfully captured visual characteristics of the tissue surrounding the malignant cells. It was capable of spotting telltale areas with greater cellular density and more cell death within samples, both of which signal more aggressive glioma types.

The tool was also able to pinpoint clinically important molecular alterations in a subset of low-grade gliomas, a subtype of glioma that is less aggressive and therefore less likely to invade surrounding tissue. Each of these changes also signals different propensity for growth, spread, and treatment response.

The tool further connected the appearance of the cells - the shape of their nuclei, the presence of edema around the cells - with the molecular profile of the tumor. This means that the algorithm can pinpoint how a cell’s appearance relates to the molecular type of a tumor.

This ability to assess the broader context around the image renders the model more accurate and closer to how a human pathologist would visually assess a tumor sample, Yu said.

The researchers say that while the model was trained and tested on glioma samples, it could be successfully retrained to identify other brain cancer subtypes.

Scientists have already designed AI models to profile other types of cancer - colon, lung, breast - but gliomas have remained particularly challenging due to their molecular complexity and huge variation in tumor cells' shape and appearance.

The CHARM tool would have to be retrained periodically to reflect new disease classifications as they emerge from new knowledge, Yu said.

"Just like human clinicians who must engage in ongoing education and training, AI tools must keep up with the latest knowledge to remain at peak performance."

Nasrallah MP, Zhao J, Tsai CC, Meredith D, Marostica E, Ligon KL, Golden JA, Yu KH.
Machine learning for cryosection pathology predicts the 2021 WHO classification of glioma.
Med. 2023 Jun 29:S2666-6340(23)00189-7. doi: 10.1016/j.medj.2023.06.002

Most Popular Now

Researchers Find Telemedicine may Help R…

Low-value care - medical tests and procedures that provide little to no benefit to patients - contributes to excess medical spending and both direct and cascading harms to patients. A...

AI Revolutionizes Glaucoma Care

Imagine walking into a supermarket, train station, or shopping mall and having your eyes screened for glaucoma within seconds - no appointment needed. With the AI-based Glaucoma Screening (AI-GS) network...

AI may Help Clinicians Personalize Treat…

Individuals with generalized anxiety disorder (GAD), a condition characterized by daily excessive worry lasting at least six months, have a high relapse rate even after receiving treatment. Artificial intelligence (AI)...

Accelerating NHS Digital Maturity: Paper…

Digitised clinical noting at South Tees Hospitals NHS Foundation Trust is creating efficiencies for busy doctors and nurses. The trust’s CCIO Dr Andrew Adair, deputy CCIO Dr John Greenaway, and...

AI can Open Up Beds in the ICU

At the height of the COVID-19 pandemic, hospitals frequently ran short of beds in intensive care units. But even earlier, ICUs faced challenges in keeping beds available. With an aging...

Mobile App Tracking Blood Pressure Helps…

The AHOMKA platform, an innovative mobile app for patient-to-provider communication that developed through a collaboration between the School of Engineering and leading medical institutions in Ghana, has yielded positive results...

Can AI Help Detect Cognitive Impairment?

Mild cognitive impairment (MCI) can be an early indicator of Alzheimer's disease or dementia, so identifying those with cognitive issues early could lead to interventions and better outcomes. But diagnosing...

AI Model Predicting Two-Year Risk of Com…

AFib (short for atrial fibrillation), a common heart rhythm disorder in adults, can have disastrous consequences including life-threatening blood clots and stroke if left undetected or untreated. A new study...

Customized Smartphone App Shows Promise …

A growing body of research indicates that older adults in assisted living facilities can delay or even prevent cognitive decline through interventions that combine multiple activities, such as improving diet...

New Study Shows Promise for Gamified mHe…

A new study published in Multiple Sclerosis and Related Disorders highlights the potential of More Stamina, a gamified mobile health (mHealth) app designed to help people with Multiple Sclerosis (MS)...

Patients' Affinity for AI Messages …

In a Duke Health-led survey, patients who were shown messages written either by artificial intelligence (AI) or human clinicians indicated a preference for responses drafted by AI over a human...

New Research Explores How AI can Build T…

In today’s economy, many workers have transitioned from manual labor toward knowledge work, a move driven primarily by technological advances, and workers in this domain face challenges around managing non-routine...